<DOC>
	<DOC>NCT01110668</DOC>
	<brief_summary>This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.</brief_summary>
	<brief_title>Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic Radiological confirmation of disease progression or intolerance to imatinib therapy at a any dose At least one measurable site of disease on CT scan at Visit2 WHO Performance Status of 0, 1 or 2 at Visit2 Patients must have normal organ, electrolyte, and marrow function at Visit1 and Visit2 Prior treatment with nilotinib or any other tyrosine kinase inhibitors except imatinib. Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks Prior or concomitant malignancies other than GIST Impaired cardiac function at Visit1 or 2 Patients with severe and/or uncontrolled concurrent medical disease Use of therapeutic coumarin derivatives Use of any medications that prolong the QT interval Use of CYP3A4 inhibitors Patients who have undergone major surgery ≤ 2 weeks prior to Visit1 or who have not recovered from side effects of such surgery Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation &lt; 2 weeks prior to Visit1 or who have not recovered from side effects of such therapy Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Unresectable</keyword>
	<keyword>metastatic gastrointestinal stromal tumor</keyword>
	<keyword>disease progression</keyword>
	<keyword>progression-free survival</keyword>
</DOC>